Herold Advisors’s Emergent Biosolutions EBS Stock Holding History

Herold Advisors’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$84K	Hold	10,000	–	–	0.02%	268
2026 Q1	$83K	Hold	10,000	–	–	0.02%	257
2025 Q4	$124K	Hold	10,000	–	–	0.03%	245
2025 Q3	$88.2K	Hold	10,000	–	–	0.02%	247
2025 Q2	$63.8K	Hold	10,000	–	–	0.01%	307
2025 Q1	$48.6K	Hold	10,000	–	–	0.01%	280
2024 Q4	$95.6K	Hold	10,000	–	–	0.02%	272
2024 Q3	$83.5K	Hold	10,000	–	–	0.02%	268
2024 Q2	$68.2K	Hold	10,000	–	–	0.02%	262
2024 Q1	$25.3K	Hold	10,000	–	–	0.01%	264
2023 Q4	$24K	Hold	10,000	–	–	0.01%	244
2023 Q3	$34K	Hold	10,000	–	–	0.01%	246
2023 Q2	$73.5K	Hold	10,000	–	–	0.02%	239
2023 Q1	$104K	Buy	+10,000	New	+$121K	0.04%	226

Other funds holding EBS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

OHA

Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

Herold Advisors's EBS Position: Q2 2026 in Review

Herold Advisors held its Emergent Biosolutions (EBS) position steady in Q2 2026 at 10,000 shares worth $84K. The position accounts for 0.02% of the portfolio, ranked #268.

Herold Advisors first reported a position in EBS in Q1 2023 and has held it in 14 quarters since. The position peaked at $124K in Q4 2025. 195 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

Herold Advisors held 10,000 shares of Emergent Biosolutions worth $84K as of Q2 2026.
Herold Advisors left its Emergent Biosolutions share count unchanged in Q2 2026.
Emergent Biosolutions made up 0.02% of Herold Advisors's portfolio in Q2 2026, its #268 holding.
Herold Advisors first reported a position in Emergent Biosolutions in Q1 2023 and has held it in 14 quarters since.
Herold Advisors's Emergent Biosolutions position peaked at $124K in Q4 2025.
195 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Herold Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.